Biohaven Ltd.
Informe acción NYSE:BHVN
Capitalización de mercado: US$5.3b
Biohaven Dividendos y recompras
Dividendo controles de criterios 0/6 Biohaven no tiene historial de pago de dividendo.
Información clave
n/a
Rentabilidad por dividendo
-10.7%
Rendimiento de la recompra
Rendimiento total para el accionista -10.7% Rendimiento futuro de los dividendos 0% Crecimiento de los dividendos n/a Próxima fecha de pago de dividendos n/a Fecha ex dividendo n/a Dividendo por acción n/a Ratio de pago n/a
Últimas actualizaciones de dividendos y recompras
Mostrar todas las actualizaciones
Biohaven: A Complicated Tale Oct 11 Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million. Oct 02
Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.
Price target increased by 9.2% to US$62.36 Sep 24
Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst Sep 23
Consensus EPS estimates fall by 21% Aug 16
New major risk - Financial position Aug 09
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment Jul 26
Independent Director recently bought US$1.0m worth of stock Jul 21
Chief Scientific Officer recently bought US$1.0m worth of stock Jun 21
Independent Director recently bought US$996k worth of stock Jun 02
Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day May 31
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors May 30
New minor risk - Share price stability May 29
Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge May 18
Consensus EPS estimates fall by 23% May 16
Independent Director recently bought US$1.0m worth of stock May 15
Independent Director recently bought US$999k worth of stock Apr 27 Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $230.000037 million. Apr 19
We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate Apr 06
Now 21% overvalued after recent price rise Mar 20 Biohaven Ltd., Annual General Meeting, Apr 30, 2024 Mar 19
Now 21% overvalued after recent price rise Mar 05
Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN) Mar 01
Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade) Feb 28
New major risk - Financial position Feb 25
Director exercised options and sold US$460k worth of stock Dec 31
Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade) Dec 08
Price target increased by 11% to US$33.17 Dec 05
Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation Dec 04
Price target increased by 7.8% to US$30.00 Nov 24
Price target increased by 7.4% to US$29.00 Nov 16
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® Oct 18
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® Oct 17
Independent Director recently bought US$402k worth of stock Oct 08
Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True Sep 27
Biohaven Ltd. Announces Positive Data from its Exploratory Electroencephalogram Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies Sep 06
Independent Director recently bought US$922k worth of stock Sep 02
Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Aug 28
Independent Director recently bought US$2.0m worth of stock Aug 08
New minor risk - Share price stability Jul 29
Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation Jul 22
Biohaven: A Promising Investment In Innovative Neurological Therapies Jun 14
Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache Jun 06
Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely? Apr 06
Biohaven's spinal muscular atrophy therapy gets FDA fast track status Feb 21
High number of new and inexperienced directors Dec 31
Biohaven Ltd: Assessing The Spinoff Dec 07
Biohaven Non-GAAP EPS of -$1.25 Nov 09
Chairman & CEO recently bought US$2.1m worth of stock Nov 01
Biohaven Ltd. Advances Development of the MoDE Platform Technology Licensed From Yale University Oct 26
Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de BHVN han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de BHVN han aumentado.
Rentabilidad por dividendo vs. Mercado Rentabilidad por dividendo de Biohaven vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de BHVN con la del mercado? Segmento Rentabilidad por dividendo Empresa (BHVN) n/a Suelo de mercado 25% (US) 1.3% Techo de mercado 25% (US) 4.3% Media de la industria (Biotechs) 2.1% Analista de previsiones (BHVN) (hasta 3 años) 0%
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de BHVN en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de BHVN en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de BHVN para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que BHVN no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
